Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: In vitro and in vivo evaluation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sharma, Deepak ^a   Maheshwari, Dipika ^a   Philip, Gilphy ^a   Rana, Ravish ^a   Bhatia, Shanu ^a   Singh, Manisha ^a   Gabrani, Reema ^a   Sharma, Sanjeev K ^a   Ali, Javed ^b   Sharma, Rakesh Kumar ^c   Dang, Shweta ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

^b HAMDARD UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; LORAZEPAM; NANOCARRIER; POLOXAMER; POLYMER; SURFACTANT; TECHNETIUM 99M; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOX BEHNKEN DESIGN; CELL VIABILITY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; DRUG UPTAKE; EX VIVO STUDY; EXPERIMENTAL DESIGN; GAMMA SCINTIGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; ISOTOPE LABELING; MALE; NANOENCAPSULATION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; POLYMERIZATION; PROCESS OPTIMIZATION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SHEEP; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPRAGUE DAWLEY RAT; SURFACE CHARGE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; VERO CELL LINE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG EFFECTS; EVALUATION STUDY; HUMAN; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PATHOLOGY; STATUS EPILEPTICUS; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LORAZEPAM; NANOPARTICLES; NASAL MUCOSA; PARTICLE SIZE; POLYMERS; RATS; SHEEP; STATUS EPILEPTICUS; TISSUE DISTRIBUTION;

EID: 84930080728     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/156010     Document Type: Article

References (51)

1. S. Shorvon, E. Perucca, and J. Engel Jr. , The Treatment of Epilepsy, Wiley-Blackwell, West Sussex, UK, 3rd edition, 2009.
2. P. N. Patsalos and B. F. D. Bourgeois, The Epilepsy Prescriber's Guide to Antiepileptic Drugs, Cambridge University Press, New York, NY, USA, 1st edition, 2010.
3. R. H. Levy, R. H. Mattson, B. S. Meldrum, and E. Perucca, Anti-Epileptic Drugs, LippincottWilliams &Wilkins, New York, NY, USA, 5th edition, 2002.
4. R. G. Strickley, "Solubilizing excipients in oral and injectable formulations, " Pharmaceutical Research, vol. 21, no. 2, pp. 201-230, 2004.
5. A. A. Date and M. S. Nagarsenker, "Parenteral microemulsions: an overview, " International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 19-30, 2008.
6. J. Medina, A. Salvadó, and A. del Pozo, "Use of ultrasound to prepare lipid emulsions of lorazepamfor intravenous injection," International Journal of Pharmaceutics, vol. 216, no. 1-2, pp. 1-8, 2001.
7. C. Holvoet, Y. Vander Heyden, and J. Plaizier-Vercammen, "Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use, " Drug Development and Industrial Pharmacy, vol. 31, no. 6, pp. 567-575, 2005.
8. N. M. Sanghavi, K. B. Choudhari, R. S. Matharu, and L. Viswanathan, "Inclusion complexation of Lorazepam with β-cyclodextrin, " Drug Development and Industrial Pharmacy, vol. 19, no. 6, pp. 701-712, 1993.
9. A. A. Kale and V. B. Patravale, "Development and evaluation of lorazepam microemulsions for parenteral delivery, " AAPS PharmSciTech, vol. 9, no. 3, pp. 966-971, 2008.
10. G. D. Anderson and R. P. Saneto, "Current oral and non-oral routes of antiepileptic drug delivery, " Advanced Drug Delivery Reviews, vol. 64, no. 10, pp. 911-918, 2012.
11. T. M. Ross, P. M. Martinez, J. C. Renner, R. G. Thorne, L. R. Hanson, and W. H. Frey II, "Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a noninvasive treatment strategy for multiple sclerosis, " Journal of Neuroimmunology, vol. 151, no. 1-2, pp. 66-77, 2004.
12. F. Wang, X. Jiang, and W. Lu, "Profiles ofmethotrexate in blood and CSF following intranasal and intravenous administration to rats, " International Journal of Pharmaceutics, vol. 263, no. 1-2, pp. 1-7, 2003.
13. S. B. Patil and K. K. Sawant, "Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery, " Journal ofMicroencapsulation, vol. 26, no. 5, pp. 432-443, 2009.
14. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable polymeric nanoparticles as drug delivery devices, " Journal of Controlled Release, vol. 70, no. 1-2, pp. 1-20, 2001.
15. R. K. Prajapati, H. S. Mahajan, and S. J. Surana, "PLGA based mucoadhesive microspheres for nasal delivery: in vitro/ex vivo studies, " Indian Journal of Novel Drug Delivery, vol. 3, pp. 9-16, 2011.
16. O. Kammona, A. H. Alexopoulos, P. Karakosta, K. Kotti, V. Karageorgiou, and C. Kiparissides, "Nanocarrier aided nasal vaccination: an experimental and computational approach," Industrial & Engineering Chemistry Research, vol. 50, no. 2, pp. 590-601, 2011.
17. R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani, and F. Atyabi, "Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents, " International Journal of Nanomedicine, vol. 6, pp. 877-895, 2011.
18. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. leBreton, and V. Préat, "PLGA-based nanoparticles: an overview of biomedical applications, " Journal of Controlled Release, vol. 161, no. 2, pp. 505-522, 2012.
19. D. Quintanar-Guerrero, E. Allémann, H. Fessi, and E. Doelker, "Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers, " Drug Development and Industrial Pharmacy, vol. 24, no. 12, pp. 1113-1128, 1998.
20. U. Bilati, E. Allémann, and E. Doelker, "Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles, " European Journal of Pharmaceutical Sciences, vol. 24, no. 1, pp. 67-75, 2005.
21. T. Betancourt, B. Brown, and L. Brannon-Peppas, "Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation, " Nanomedicine, vol. 2, no. 2, pp. 219-232, 2007.
22. J. Cheng, B. A. Teply, I. Sherifi et al., "Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery, " Biomaterials, vol. 28, no. 5, pp. 869-876, 2007.
23. C. Wilhelm, C. Billotey, J. Roger, J. N. Pons, J.-C. Bacri, and F. Gazeau, "Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating, " Biomaterials, vol. 24, no. 6, pp. 1001-1011, 2003.
24. Y. Huang and M. D. Donovan, "Microsphere transport pathways in the rabbit nasal mucosa, " International Journal of Pharmaceutics, vol. 1, pp. 298-309, 1996.
25. L. R. Hanson andW. H. Frey II, "Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease, " BMC Neuroscience, vol. 9, no. 3, article S5, 2008.
26. S. Talegaonkar and P. R. Mishra, "Intranasal delivery: an approach to bypass the blood brain barrier, " Indian Journal of Pharmacology, vol. 36, no. 3, pp. 140-147, 2004.
27. J. Nah, Y. Jeong, and J. Koh, "Drug release from nanoparticles of Poly(DL-lactide-co-glycolide), " Korean Journal of Chemical Engineering, vol. 17, no. 2, pp. 230-236, 2000.
28. E. Ghasemian, A. Vatanara, A. R. Najafabadi, M. R. Rouini, K. Gilani, and M. Darabi, "Preparation, characterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design, " DARU Journal of Pharmaceutical Sciences, vol. 21, article 68, 2013.
29. J. Hao, X. Fang, Y. Zhou et al., "Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design, " International Journal of Nanomedicine, vol. 6, pp. 683-692, 2011.
30. C. M. Noronha, A. F. Granada, S. M. de Carvalho, R. C. Lino, M. V. D. O. B. Maciel, and P. L. M. Barreto, "Optimization of α-tocopherol loaded nanocapsules by the nanoprecipitation method, " Industrial Crops and Products, vol. 50, pp. 896-903, 2013.
31. M. Yasir and U. V. S. Sara, "Preparation and optimization of haloperidol loaded solid lipid nanoparticles by Box-Behnken design, " Journal of Pharmacy Research, vol. 7, no. 6, pp. 551-558, 2013.
32. G. Sharma, A. K. Mishra, P. Mishra, and A. Misra, "Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies," AAPS PharmSciTech, vol. 10, no. 4, pp. 1321-1330, 2009.
33. N. Chigumbu, S. Iyuke, V. Pillay, and S. Ndlovu, "In vitro evaluation of the physicochemical effects of drug loaded carbon nanotubes on toxicity, " Journal of Nanomedicine and Nanotechnology, vol. 3, no. 4, 2012.
34. A. P. Ranjan, A. Mukerjee, L. Helson, and J. K. Vishwanatha, "Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy, " Journal of Nanobiotechnology, vol. 10, article 38, 2012.
35. A. R. Pérez, E. G. García, A. Z. Mancera et al., "Designing and evaluation of sodium selenite nanoparticles in vitro to improve selenium absorption in ruminants, " Veterinary Research Communications, vol. 34, no. 1, pp. 71-79, 2010.
36. S. Jain, A. Mittal, A. K. Jain, R. R. Mahajan, and D. Singh, "Cyclosporin a loaded PLGA nanoparticle: preparation, optimization, in-Vitro characterization and stability studies, " Current Nanoscience, vol. 6, no. 4, pp. 422-431, 2010.
37. S. Manoochehri, B. Darvishi, G. Kamalinia et al., "Surface modification of PLGA nanoparticles via human serumalbumin conjugation for controlled delivery of docetaxel, " DARU, Journal of Pharmaceutical Sciences, vol. 21, article 58, no. 1, 2013.
38. R. R. Pillai, S. N. Somayaji, M. Rabinovich, M. C. Hudson, and K. E. Gonsalves, "Nafcillin-loaded PLGAnanoparticles for treatment of osteomyelitis, " Biomedical Materials, vol. 3, no. 3, Article ID 034114, 2008.
39. R. K. Averineni, G. V. Shavi, A. K. Gurram et al., "PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation, " Bulletin of Materials Science, vol. 35, no. 3, pp. 319-326, 2012.
40. A. Budhian, S. J. Siegel, and K. I. Winey, "Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content, " International Journal of Pharmaceutics, vol. 336, no. 2, pp. 367-375, 2007.
41. T. Feczkó, J. Tóth, G. Dósa, and J. Gyenis, "Influence of process conditions on the mean size of PLGA nanoparticles, " Chemical Engineering and Processing: Process Intensification, vol. 50, no. 8, pp. 846-853, 2011.
42. R. M. Mainardes and R. C. Evangelista, "PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution, " International Journal of Pharmaceutics, vol. 290, no. 1-2, pp. 137-144, 2005.
43. U. Seju, A. Kumar, and K. K. Sawant, "Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-tobrain delivery: in vitro and in vivo studies, " Acta Biomaterialia, vol. 7, no. 12, pp. 4169-4176, 2011.
44. S. A. Joshi, S. S. Chavhan, and K. K. Sawant, "Rivastigmineloaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies," European Journal of Pharmaceutics and Biopharmaceutics, vol. 76, no. 2, pp. 189-199, 2010.
45. X. Song, Y. Zhao, S. Hou et al., "Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 2, pp. 445-453, 2008.
46. T. Musumeci, C. A. Ventura, I. Giannone et al., "PLA/PLGA nanoparticles for sustained release of docetaxel, " International Journal of Pharmaceutics, vol. 325, no. 1-2, pp. 172-179, 2006.
47. J. Panyam, D. William, A. Dash, D. Leslie-Pelecky, and V. Labhasetwar, "Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles," Journal of Pharmaceutical Sciences, vol. 93, no. 7, pp. 1804-1814, 2004.
48. S. Kalimouttou, M. Skiba, P. Bon, P. Dechelotte, P. Arnaud, and M. Lahiani-Skiba, "Sinefungin-PLGA nanoparticles: drug loading, Characterization, in vitro drug release and in vivo studies, " Journal of Nanoscience and Nanotechnology, vol. 9, no. 1, pp. 150-158, 2009.
49. R. M. Mainardes, M. P. D. Gremiãao, and R. C. Evangelista, "Thermoanalytical study of praziquantel-loaded PLGA nanoparticles, " Brazilian Journal of Pharmaceutical Sciences, vol. 42, no. 4, pp. 523-530, 2006.
50. B. Sylaja and S. Srinivasan, "Experimental and theoretical investigation of spectroscopic properties of diazepam, " International Journal of ChemTech Research, vol. 4, no. 1, pp. 361-376, 2012.
51. Y. Ma, Y. Zheng, K. Liu et al., "Nanoparticles of poly(Lactide-Co-Glycolide)-d-a-Tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment, " Nanoscale Research Letters, vol. 5, no. 7, pp. 1161-1169, 2010.